A Phase 2a, Randomized, Double-blind, Parallel Group, Placebo-controlled, Multi-center Study To Assess The Efficacy And Safety Profile Of Pf-06651600 In Subjects With Moderate To Severe Active Rheumatoid Arthritis With An Inadequate Response To Methotrexate
Phase of Trial: Phase II
Latest Information Update: 16 Aug 2017
At a glance
- Drugs PF 6651600 (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Pfizer
- 14 Jul 2017 Planned End Date changed from 1 Mar 2018 to 29 Mar 2018.
- 14 Jul 2017 Planned primary completion date changed from 1 Mar 2018 to 29 Mar 2018.
- 10 Jun 2017 Biomarkers information updated